临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Dofetilide
中文名称:多非利特
CAS号:115256-11-6
分子式: C19H27N3O5S2 分子量: 441.56
产品形式: free base
研发状态: Recruiting
研发用途: Long QT Syndrome
研究机构: Thryv Therapeutics Inc.
研发日期: March 12 2023
研发阶段: Phase 1 : Phase 2
Dofetilide (UK-68798) is a selective potassium channel ((hERG)) blocker, used as a Class III antiarrhythmic drug.
Tezacaftor (VX-661)
中文名称:替扎卡托
CAS号:1152311-62-0
分子式: C26H27F3N2O6 分子量: 520.50
产品形式: free base
研发状态: Completed
研发用途: Cystic Fibrosis
研究机构: Vertex Pharmaceuticals Incorporated
研发日期: Jun-15
研发阶段: Phase 3
Tezacaftor (VX-661) is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
Lesinurad sodium
中文名称:Lesinurad钠盐
CAS号:1151516-14-1
分子式: C17H13BrN3NaO2S 分子量: 426.26
产品形式: Sodium
研发状态: Terminated
研发用途: Pulmonary Arterial Hypertension
研究机构: Actelion
研发日期: July 7 2021
研发阶段: Phase 4
Lesinurad (Selexipag, RDEA-594) sodium (Zurampic) is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout. Lesinurad sodium inhibits the uric acid transporter URAT1 and Kidney transporter OAT with IC50/Km of 4.3 μM/0.85 μM and 3.5 μM/2 μM for OAT1 and OAT3, respectively.
Docetaxel (RP56976)
中文名称:多烯紫杉醇;多西他赛
CAS号:114977-28-5
分子式: C43H53NO14 分子量: 807.88
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Squamous Cell Non-small Cell Lung Cancer
研究机构: Shanghai JMT-Bio Inc.
研发日期: May 1 2024
研发阶段: Phase 2 : Phase 3
Docetaxel (RP56976, NSC 628503), an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
XL888
CAS号:1149705-71-4
分子式: C29H37N5O3 分子量: 503.64
产品形式: free base
研发状态: Completed
研发用途: Colorectal Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Recurrent Colorectal Carcinoma; Recurrent Pancreatic Carcinoma; Stage III Colorectal Cancer; Stage III Pancreatic Cancer; Stage IIIA Colorectal Cancer; Stage IIIB Colorectal Cancer; Stage IV Colorectal Cancer; Stage IV Pancreatic Cancer; Stage IVA Colorectal Cancer; Stage IVA Pancreatic Cancer; Stage IVB Colorectal Cancer; Stage IVB Pancreatic Cancer; Unresectable Pancreatic Carcinoma
研究机构: Emory University; Merck Sharp & Dohme LLC; Exelixis; National Institutes of Health (NIH); National Cancer Institute (NCI)
研发日期: July 7 2017
研发阶段: Phase 1
XL888 is an ATP-competitive inhibitor of HSP90 with IC50 of 24 nM. Phase 1.
Fondaparinux Sodium (Org 31540)
中文名称:磺达肝癸钠
CAS号:114870-03-0
分子式: C31H43N3O49S8.10Na 分子量: 1728.08
产品形式: Sodium salt
研发状态: Completed
研发用途: Venous Thrombosis; Pulmonary Embolism
研究机构: University of Pittsburgh; GlaxoSmithKline
研发日期: Feb-07
研发阶段: Phase 2
Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
